Nghiên cứu đặc điểm lâm sàng, cận lâm sàng của bệnh nhân ung thư tuyến giáp biệt hóa kháng 113I

Abstract

Objective: To determine clinical characteristics of RAI (radioiodine) refractory differentiated thyroid carcinoma (DTC) patients. Subject and method: 123 post-surgical and treated with ¹³¹I differentiated thyroid carcinoma patients, diagnosed RAI refractory were enrolled in the study in 108 Military Central Hospital and The Military Institute of Medical radiology and Oncology from January 2015 to December 2020. Result: RAI refractory differentiated thyroid carcinoma (R-DTC) was more frequently seen in middle aged, female patients (female to male ratio 3.1/1). Papillary and folicullar carcinoma accounted for 95.9% and 4.1% respectively. 54.5% of patients were in stage I and 26.8% in stage VI (AJCC 7). The distant metastases were detected in 2.4% of patients. The median of time from initial diagnosis to RAI refractory was 25.4 months. ¹³¹I treatment courses were 2.76 ± 1.3. The mean total dose was 358.6mCi. 39.8% of the patients were in group I; 48% in group II and the rate of group III and IV were 3.3% and 8.1% respectively according to the ATA RAI refractory classification of DTC. 79.7% of patients had one RAI refractory lesion; 74.1% had metastasis in the neck lymph nodes and 17.9% had recurrent malignant lesions in the thyroid bed. Conclusion: Papillary thyroid carcinoma is frequently seen R-DTC after ¹³¹I treatment. R-DTC recurrent lesions are situated mostly in thyroid beds, lymph node with distant multiple metastases.